Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Johnson & Johnson charged by New York with civil insurance fraud over opioid claims

Published 17/09/2020, 17:46
Updated 17/09/2020, 17:50
© Reuters. FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the NYSE in New York

By Jonathan Stempel

NEW YORK (Reuters) - New York state filed civil charges on Thursday accusing Johnson & Johnson (N:JNJ) of insurance fraud for downplaying the risks of opioid painkillers, including to doctors and elderly patients.

J&J and its Janssen Pharmaceuticals affiliate were accused of targeting elderly patients for opioid treatment despite the risks of side effects such as falls, fractures and neuropsychiatric symptoms.

The company was also accused of employing marketing materials, "seemingly independent" advocacy groups and "key opinion leaders" to dismiss opioid addiction as a myth.

"Misrepresentation of opioids to consumers for profit is inexcusable," Governor Andrew Cuomo said in a statement.

In a statement, J&J called its marketing and promotion of opioids "appropriate and responsible. Janssen provided these medicines for doctors treating patients suffering from pain and worked with regulators to provide appropriate information about their risks and benefits."

The charges by New York's Department of Financial Services are the fourth in its opioid industry probe, following charges against Teva Pharmaceutical (NYSE:TEVA) Industries Ltd (TA:TEVA) and Allergan (NYSE:AGN) Plc, Endo International Plc (O:ENDP) and Mallinckrodt Plc (N:MNK).

J&J, based in New Brunswick, New Jersey, has proposed paying $4 billion to settle opioid claims by U.S. states, cities and counties.

It is separately appealing a $465 million judgment in Oklahoma from last November over its opioid marketing there.

New York said J&J manufactured opioid products in the state including Nucynta and the fentanyl patch Duragesic, and received multiple U.S. Food and Drug Administration letters challenging its Duragesic marketing claims.

The state also said J&J's "Norman Poppy," developed in 1994, once accounted for as much as 80% of the global supply for oxycodone raw materials.

Oxycodone is the main ingredient in OxyContin, made by the now-bankrupt Purdue Pharma LP.

The U.S. Centers for Disease Control and Prevention has said opioids have contributed to more than 400,000 deaths since 1997.

© Reuters. FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the NYSE in New York

J&J was charged with violating two New York insurance laws, with civil penalties of up to $5,000 per violation.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.